Comparison of Rapid Aflibercept and Brolucizumab T&E in wAMD
Status:
Not yet recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
The currently widely established and preferred protocol for the treatment of wet age-related
macular degeneration includes a loading phase of three monthly injections without interim
adaptation or treatment according to disease activity, thereafter following a T&E strategy
with treatment adaptation in increments of 2-4 weeks according to disease activity. Based on
pharmacological considerations regarding the vitreal half-life of the drugs, the aim of this
prospective explorative study is to test whether an early extension of treatment intervals
without a loading phase is an option without compromising functional outcomes. Based on a
superiority of Afl compared to Ran with regard to achieving a dry retina after one year and
based on studies, but in the absence of real-life experience with Bro, it seems of interest
to test how far Afl and Bro are comparable in terms of their potential to extend the
treatment intervals over 12 months, the time to dryness of the retina, and number of
injections. Also, it is of high clinical relevance to demonstrate efficacy with longer
initial treatment intervals compared to the current possibly over-treating loading-phase with
three four-weekly injections.